The abstract is read at the publisher; the summary is JClub's.
Programmable non-viral delivery of dCas9-KRAB RNPs silences the oncogenic fusion EWSR1-FLI1 in Ewing sarcoma, producing potent anti-tumor effects in xenografts and EWS-related PDXs.
- Why it matters: Clinical CRISPR use is limited by safe, effective intracellular delivery, and hard-to-drug oncogenic drivers need selective repression strategies.
- What they did: The study built a non-viral PAMAM polymer system with guanidino functionalization to deliver dCas9-KRAB as RNP payloads, then targeted EWSR1-FLI1 in established xenografts and EWS patient-derived xenografts.
- The result: EWSR1-FLI1 repression was robust after efficient RNP delivery, enabling strong anti-tumor activity and supporting adaptation of the platform to other oncogenes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.